WEST CHESTER, Ohio, Nov. 20 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company and leader in cardiac surgical ablation systems, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 19th Annual Health Care Conference at the Pierre Hotel in New York City on Tuesday, November 27th, at 3:00 p.m. ET.
A live web cast and recording of the presentation will be available for 30 days following the presentation on AtriCure’s Investor Relations page at www.atricure.com.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and cardiac related surgical procedures, but to date has not cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF. AtriCure’s left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.
jpiton@atricure.com
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer of
AtriCure, Inc., +1-513-755-4561, jpiton@atricure.com
Web site: http://www.atricure.com//
